Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for gastrointestinal diseases. Founded in 2018 and headquartered in Buffalo Grove, Illinois, Phathom Pharmaceuticals possesses exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium-competitive acid blocker (PCAB). This groundbreaking medication inhibits acid secretion in the stomach and has shown significant clinical benefits, providing rapid, potent, and sustained acid suppression.
Phathom's flagship product, VOQUEZNA® (vonoprazan), is now FDA-approved and available in the U.S. for treating Erosive Esophagitis (Erosive GERD) and relieving associated heartburn in adults. VOQUEZNA is the first new class of acid suppression medication approved in the U.S. in over 30 years, offering a novel mechanism of action distinct from other treatments. Its efficacy, demonstrated in clinical trials, surpasses that of traditional proton pump inhibitors (PPIs), showcasing strong healing rates and durable results.
In addition to treating GERD, Phathom is developing vonoprazan for use in combination with antibiotics to treat Helicobacter pylori (H. pylori) infection. VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® are expected to be commercially available soon, providing comprehensive treatment regimens co-packaged with antibiotics.
Phathom Pharmaceuticals is actively engaged in several key initiatives and collaborations. Recent milestones include the U.S. commercial availability of VOQUEZNA, the completion of Phase 3 trials for Non-Erosive GERD, and the amendment of a term loan facility enhancing financial flexibility. Their innovative approach and dedicated national sales force have driven significant market penetration, with VOQUEZNA now estimated to cover 60 million lives through partnerships with major pharmacy benefit managers.
Phathom is committed to addressing unmet medical needs by offering co-pay assistance programs to ensure accessibility and affordability for patients. They continue to explore new treatment options and expand the indications for vonoprazan through ongoing research and development efforts.
For more information, visit the company’s website at www.phathompharma.com, and follow them on LinkedIn and X (formerly Twitter).
Phathom Pharmaceuticals (Nasdaq: PHAT) has completed patient enrollment in its pivotal Phase 3 clinical trial, PHALCON-HP, evaluating vonoprazan for H. pylori infection. The trial includes over 1,000 patients and aims to provide topline results in Q2 2021. The company also expects to submit a New Drug Application for H. pylori treatment in H2 2021. Vonoprazan, a potassium-competitive acid blocker, has shown promise in eradicating H. pylori and has received FDA Fast Track designation. The trial's success could significantly address rising antibiotic resistance.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced a public offering of 2,250,000 shares at $42.00 per share, aiming for gross proceeds of $94.5 million before expenses. The offering is expected to close around December 21, 2020. Proceeds will fund clinical development of vonoprazan, a treatment for gastrointestinal diseases, and cover general corporate needs. Underwriters have a 30-day option to purchase an additional 337,500 shares. Jefferies, Evercore ISI, Guggenheim Securities, and BMO Capital Markets are managing the offering.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced plans for a public offering of 2,250,000 shares of common stock, with an option for underwriters to purchase an additional 337,500 shares. The offering aims to fund the clinical development of vonoprazan, a treatment for gastrointestinal diseases. The net proceeds will also support working capital and pre-commercial activities. The offering is subject to market conditions, and a detailed prospectus will be filed with the SEC.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced an expansion of its vonoprazan development program to include non-erosive reflux disease (NERD). This condition affects over 65 million U.S. patients with GERD, with two-thirds suffering from NERD. The program will assess dosage flexibility through clinical trials, with a Phase 2 trial expected to start in mid-2021. The company aims to address limitations in current treatments, utilizing feedback from the FDA. Phathom is simultaneously conducting pivotal trials for erosive esophagitis and H. pylori eradication.
Phathom Pharmaceuticals (Nasdaq: PHAT) announces the completion of patient enrollment in its pivotal Phase 3 clinical trial, PHALCON-EE, for vonoprazan, targeting the healing and maintenance of erosive esophagitis (EE) and heartburn relief. The trial exceeded its enrollment goal of 1,000 patients, with topline results expected in the second half of 2021. This trial complements another study, PHALCON-HP, assessing vonoprazan in H. pylori eradication. Vonoprazan has demonstrated promising efficacy and safety as a potassium-competitive acid blocker, recently receiving Fast Track designation from the FDA.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its management team will participate in two virtual investor conferences in December 2020:
- Evercore ISI 3rd Annual HealthCONx Conference
Date: December 1, 2020
Live Presentation Time: 10:55 am ET - Piper Sandler 32nd Annual Virtual Healthcare Conference
Date: December 2, 2020
Pre-recorded presentation available online
Additionally, one-on-one meetings will be held during these events. For access to the presentations, visit Phathom's website.
Phathom Pharmaceuticals (Nasdaq: PHAT) will host a virtual Investor Day on December 14, 2020, from 1 PM to 3:30 PM ET. The event will feature members of Phathom's management team and gastroenterology experts discussing the company's pipeline and commercial strategy. Interested participants can pre-register for the event. A replay and presentation slides will be available post-event on Phathom's website.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced that its management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 3:15 p.m. GMT (10:15 a.m. ET). The conference runs from November 17-19, 2020, where the team will also engage in one-on-one meetings. Interested parties can access the live webcast and recorded presentations via the Phathom website. The company specializes in developing treatments for gastrointestinal diseases, focusing on the novel potassium competitive acid blocker, vonoprazan.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported third-quarter 2020 financial results and provided updates on its pivotal Phase 3 clinical trials for vonoprazan. The company expects to complete enrollment in the PHALCON-EE trial by year-end 2020 and in the PHALCON-HP trial by Q1 2021. Top-line results are anticipated in mid-2021. The net loss for Q3 2020 was $34.1 million, down from $68.1 million in Q3 2019. Cash and equivalents stood at $226.4 million as of September 30, 2020. Phathom is enhancing its team with seasoned biopharmaceutical leaders in preparation for vonoprazan’s potential launch.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 3:30 p.m. ET. The management team will engage in one-on-one meetings throughout the virtual conference, which runs from September 14-18, 2020. Phathom focuses on developing novel treatments for gastrointestinal diseases, including a late-stage development drug, vonoprazan, aimed at treating acid-related disorders. Recorded sessions will be available for 60 days post-event.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
What does Phathom Pharmaceuticals focus on?
What is vonoprazan?
What conditions does VOQUEZNA treat?
What makes VOQUEZNA unique?
Are there other products in development at Phathom?
Where is Phathom Pharmaceuticals headquartered?
When was Phathom Pharmaceuticals incorporated?
What recent financial milestone did Phathom achieve?
How can patients afford VOQUEZNA?
Where can I find more information about Phathom Pharmaceuticals?
